#1 out of 1344.4K est. views
health1d ago
Single-dose psychedelic treatment may ease depression, research finds
- A phase 2a trial in London tested a single 21.5 mg dose of DMT with psychotherapy in 34 depressed participants.
- Two weeks after treatment, DMT participants showed greater depressive-symptom reduction than placebo.
- Effects persisted for up to three months after starting the trial, according to researchers.
- DMT was well tolerated with no serious adverse events reported in the trial.
- Experts caution that psychedelic experiences can be frightening, underscoring need for careful oversight.
- Around 332 million people worldwide suffer from depression, with many not fully responding to standard antidepressants.
- The Czech Republic recently legalised medical psilocybin for psychotherapy, signalling regulatory shifts in Europe.
- Psychedelics are not yet fully authorised for clinical use in Europe; trials and compassionate-use programmes remain common.
- Researchers look to psychedelics as promising candidates for treating depression with unmet needs.
- The trial was phase 2a, indicating preliminary evidence and dose-finding goals for future studies.
Vote 1



:max_bytes(150000):strip_icc()/VWH-GettyImages-2160200162-6b40932d59664e61b0d32a9da7e7cc81.jpg)



